Preventing the interaction between the cellular adhesion integrin α4β7 and endothelial ligand mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) is a validated strategy for Crohn’s disease and ulcerative colitis treatment. Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical efficacy data on SPY-001, a long-acting monoclonal antibody targeting integrin α4β7.
Researchers from Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical data for SPY-002, a novel extended half-life, fully human IgG1 monoclonal antibody (MAb) targeting tumor necrosis factor (TNF)-like ligand 1A (TL1A), being developed for the treatment of inflammatory bowel disease (IBD).
Jasper Therapeutics Inc. has presented data at the AAAAI 2024 conference regarding its CD117-targeting antibody briquilimab and its potential use in allergy and CD117-triggered anaphylactic reactions.
Plexin domain containing 2 (PLXDC2) is expressed on the surface of several cell types, such as macrophages, dendritic or epithelial cells. Its activation reduces oxidative stress and rebalances the immune response and decreases inflammation. Its activation has been seen to improve disease severity in models of rheumatoid arthritis, while its blockade or loss exacerbates the severity of dextran sulfate sodium (DSS)-induced colitis. Researchers hence tested the PLXDC2 agonist PX-04 (Landos Biopharma Inc.) in a DSS-induced murine model of colitis.
At the ongoing European Crohn’s and Colitis Organization (ECCO) meeting, researchers from Kangpu Biopharmaceuticals Ltd. presented efficacy data on KPG-818, a lenalidomide analogue, in a mouse model that recapitulates Crohn’s disease and ulcerative colitis.
Proto-oncogene Vav (VAV1) is a guanine exchange factor that is crucial for T- and B-cell receptor signaling. Assays in Vav1-knockout murine models had previously demonstrated diminished effector functions and resistance to autoimmune disease. Monte Rosa Therapeutics AG has presented data on the VAV1 inhibitor MRT-6160, a first-in-class molecule that targets VAV1 for proteasomal degradation, thought to potentially treat autoimmune diseases through the degradation of VAV1.
Researchers from the Peking University Health Science Center have developed a murine model of RSV infection based on the knockout of the Rag2 gene using CRISPR/Cas9 (Rag2-/- mice).
Helping executive and investors prepare for better economic times is a strong theme in the upcoming BIO CEO 2024 conference, which runs Feb. 26 and 27 in New York. The annual conference, sponsored by the Biotechnology Innovation Organization, is designed to present a broad, unbiased view of investment opportunities. Panels of experts are set to discuss hot therapeutic areas and the key business issues facing companies and the industry.
Researchers from the Virginia-Maryland College of Veterinary Medicine have developed a new murine model of Eastern equine encephalitis virus infection that resembles human disease with its associated neurologic sequelae.
Previous research has shown that upon activation, platelets release CXCL4, influencing replication and propagation of dengue virus (DENV) by increasing the capacity of DENV-2 subtype to bind the CXCR3 receptor on monocytes. At the recent Viruses conference held in Barcelona, researchers from the Translational Health Science & Technology Institute reported the preclinical profile of a CXCR3 antagonist under investigation for the treatment of DENV.
RSS
